Free tool
FAERS Monitor: Atoncy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220320 or its brand name (Atoncy, Atomoxetine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,613
Serious
2,294
88% of reports
Hospitalization
1,386
Death reported
1,293
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use786
- drug ineffective670
- epilepsy620
- pain618
- confusional state613
- hypoaesthesia609
- maternal exposure during pregnancy608
- psoriatic arthropathy598
- swelling590
- rheumatoid arthritis589
- abdominal pain upper588
- systemic lupus erythematosus578
- type 2 diabetes mellitus577
- pericarditis572
- condition aggravated571
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 27 |
| 2006 | 9 |
| 2007 | 25 |
| 2010 | 2 |
| 2011 | 6 |
| 2012 | 19 |
| 2013 | 17 |
| 2014 | 22 |
| 2015 | 39 |
| 2016 | 18 |
| 2017 | 21 |
| 2018 | 46 |
| 2019 | 58 |
| 2020 | 48 |
| 2021 | 75 |
| 2022 | 147 |
| 2023 | 197 |
| 2024 | 445 |
| 2025 | 928 |
| 2026 | 453 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,546 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pericarditisSignal | 572 | 283.7 | 263.4 | 155,500 |
| epilepsySignal | 620 | 166.6 | 155.4 | 99,965 |
| type 2 diabetes mellitusSignal | 577 | 140.3 | 130.5 | 78,452 |
| systemic lupus erythematosusSignal | 578 | 133.2 | 123.9 | 74,619 |
| psoriatic arthropathySignal | 598 | 120.3 | 112.1 | 69,752 |
| maternal exposure during pregnancySignal | 608 | 55.3 | 51.5 | 32,268 |
| swellingSignal | 590 | 51.1 | 47.5 | 28,853 |
| rheumatoid arthritisSignal | 589 | 42.0 | 39.1 | 23,522 |
| hypoaesthesiaSignal | 609 | 32.9 | 30.7 | 18,850 |
| confusional stateSignal | 613 | 30.6 | 28.6 | 17,621 |
| abdominal pain upperSignal | 588 | 23.1 | 21.5 | 12,468 |
| condition aggravatedSignal | 571 | 15.1 | 14.1 | 7,625 |
| painSignal | 618 | 8.1 | 7.6 | 3,954 |
| off label useSignal | 786 | 7.2 | 6.8 | 4,393 |
| drug ineffectiveSignal | 670 | 4.1 | 3.8 | 1,667 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.